DK0540588T3 - Præparat, som tilvejebringer forbedret clearance af bioaktive stoffer fra blodstrømmen - Google Patents
Præparat, som tilvejebringer forbedret clearance af bioaktive stoffer fra blodstrømmenInfo
- Publication number
- DK0540588T3 DK0540588T3 DK91913278.7T DK91913278T DK0540588T3 DK 0540588 T3 DK0540588 T3 DK 0540588T3 DK 91913278 T DK91913278 T DK 91913278T DK 0540588 T3 DK0540588 T3 DK 0540588T3
- Authority
- DK
- Denmark
- Prior art keywords
- bioactive substances
- blood stream
- providing improved
- improved clearance
- ligand
- Prior art date
Links
- 230000000975 bioactive effect Effects 0.000 title abstract 3
- 239000000126 substance Substances 0.000 title abstract 3
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 4
- 230000001413 cellular effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nanotechnology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK176290A DK176290D0 (da) | 1990-07-24 | 1990-07-24 | Terapeutisk og diagnostisk praeparat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0540588T3 true DK0540588T3 (da) | 1995-11-06 |
Family
ID=8107861
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK176290A DK176290D0 (da) | 1990-07-24 | 1990-07-24 | Terapeutisk og diagnostisk praeparat |
| DK91913278.7T DK0540588T3 (da) | 1990-07-24 | 1991-07-24 | Præparat, som tilvejebringer forbedret clearance af bioaktive stoffer fra blodstrømmen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK176290A DK176290D0 (da) | 1990-07-24 | 1990-07-24 | Terapeutisk og diagnostisk praeparat |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0540588B1 (da) |
| JP (1) | JPH05509092A (da) |
| AT (1) | ATE123951T1 (da) |
| AU (1) | AU659092B2 (da) |
| CA (1) | CA2087971A1 (da) |
| DE (1) | DE69110679T2 (da) |
| DK (2) | DK176290D0 (da) |
| FI (1) | FI930269A7 (da) |
| GR (1) | GR3017362T3 (da) |
| NO (1) | NO930218L (da) |
| WO (1) | WO1992001469A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525338A (en) * | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| US5612034A (en) * | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
| GB9705521D0 (en) | 1997-03-18 | 1997-05-07 | Univ Sheffield | The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue |
| KR100452125B1 (ko) * | 2002-07-30 | 2004-10-12 | 주식회사 바이오알앤즈 | 음식물쓰레기의 발효 소멸화 능력을 보유한 신규한 균주바실러스 서브틸리스 brd-007 및 이를 이용한음식물 쓰레기의 발효 소멸화용 미생물제제 |
| IL182956A0 (en) * | 2007-05-03 | 2008-01-20 | Yeda Res & Dev | Glycan modified soluble receptors and binding proteins and their use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0149709B2 (en) * | 1983-07-29 | 1995-11-29 | Milton David Goldenberg | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
| US4624846A (en) * | 1983-07-29 | 1986-11-25 | Immunomedics, Inc. | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
| AU595173B2 (en) * | 1985-01-08 | 1990-03-29 | General Hospital Corporation, The | Method and use for site-specific activation of substances |
| US4916070A (en) * | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
| US4863713A (en) * | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| US4932412A (en) * | 1986-12-18 | 1990-06-12 | Immunomedics, Inc. | Intraoperative and endoscopic tumor detection and therapy |
| US4859449A (en) * | 1987-09-14 | 1989-08-22 | Center For Molecular Medicine And Immunology | Modified antibodies for enhanced hepatocyte clearance |
| GB8728856D0 (en) * | 1987-12-10 | 1988-01-27 | Bradwell A R | Tumour-locating agents & method of locating tumours |
| US4925648A (en) * | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
-
1990
- 1990-07-24 DK DK176290A patent/DK176290D0/da not_active Application Discontinuation
-
1991
- 1991-07-24 AU AU82828/91A patent/AU659092B2/en not_active Ceased
- 1991-07-24 CA CA002087971A patent/CA2087971A1/en not_active Abandoned
- 1991-07-24 DE DE69110679T patent/DE69110679T2/de not_active Expired - Fee Related
- 1991-07-24 WO PCT/DK1991/000215 patent/WO1992001469A1/en not_active Ceased
- 1991-07-24 DK DK91913278.7T patent/DK0540588T3/da active
- 1991-07-24 EP EP91913278A patent/EP0540588B1/en not_active Expired - Lifetime
- 1991-07-24 FI FI930269A patent/FI930269A7/fi not_active Application Discontinuation
- 1991-07-24 JP JP3512515A patent/JPH05509092A/ja active Pending
- 1991-07-24 AT AT91913278T patent/ATE123951T1/de not_active IP Right Cessation
-
1993
- 1993-01-22 NO NO93930218A patent/NO930218L/no unknown
-
1995
- 1995-09-13 GR GR950402478T patent/GR3017362T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU8282891A (en) | 1992-02-18 |
| CA2087971A1 (en) | 1992-01-25 |
| ATE123951T1 (de) | 1995-07-15 |
| WO1992001469A1 (en) | 1992-02-06 |
| FI930269L (fi) | 1993-03-22 |
| NO930218D0 (no) | 1993-01-22 |
| FI930269A7 (fi) | 1993-03-22 |
| DE69110679D1 (de) | 1995-07-27 |
| NO930218L (no) | 1993-03-24 |
| JPH05509092A (ja) | 1993-12-16 |
| GR3017362T3 (en) | 1995-12-31 |
| EP0540588A1 (en) | 1993-05-12 |
| EP0540588B1 (en) | 1995-06-21 |
| AU659092B2 (en) | 1995-05-11 |
| DE69110679T2 (de) | 1995-11-09 |
| DK176290D0 (da) | 1990-07-24 |
| FI930269A0 (fi) | 1993-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19775096I2 (de) | Desulfatohirudine Verfahren zu ihrer Herstellung und pharmazeutische Mittel | |
| DE69230670D1 (de) | Zusammensetzungen, die eine blutgerinnselpolymermatrix zur verabreichung von osteogenen proteinen enthalten | |
| ATE2271T1 (de) | 4-(substituierte thiazolyl)-3-hydroxy-3-pyrrolin2,5-dion-verbindungen, verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzung. | |
| DE68903846D1 (de) | Neue galenische form von fenofibrat. | |
| ATE7697T1 (de) | Substituierte pyrazinyl-1,2,4-oxadiazol-5-one, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung. | |
| BR9711098B1 (pt) | compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas. | |
| DE69131813D1 (de) | Amido-3-Pyrazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen | |
| ATE26705T1 (de) | 1-carboxyalkanoylindolin-2-carbonsaeuren und deren derivate, verfahren zu ihrer herstellung, und pharmazeutische praeparate, die diese verbindungen enthalten. | |
| BR9200252A (pt) | Agente para aplicacao oral,peca moldada para aplicacao oral,produto,processo para a preparacao de um agente,processo para preparacao de pecas moldadas e aplicacao de uma peca moldada | |
| FI103712B1 (fi) | Menetelmä uuden, huokoisen, homogeenisen, lyofilisoidun farmaseuttisen yksikköannosmuodossa olevan valmisteen valmistamiseksi | |
| MX9102580A (es) | Nuevas benzodiacepinonas, procedimiento para su preparacion y composicion farmaceutica que las contiene. | |
| ATE222897T1 (de) | Substituierte thiazolidinedione derivate, ihre herstellung und pharmazeutische zusammensetzungen,die sie enthalten | |
| NL190399C (nl) | IJzer-bevattend eiwitmateriaal, bereiding daarvan, en farmaceutisch preparaat voor de behandeling van sideropene anaemie. | |
| MX24890A (es) | Polipeptido sintetico, procedimiento par su preparacion y composicion farmaceutica que lo contiene. | |
| DK0540588T3 (da) | Præparat, som tilvejebringer forbedret clearance af bioaktive stoffer fra blodstrømmen | |
| ES499363A0 (es) | Procedimiento para la obtencion de derivados de fenilpipera-cina de 1,3,4-oxadiazolilfenoles | |
| MX9205744A (es) | 3-(n-isopropil-n-n-propilamino)-5-(n-isopropil)carbamoilcromano, proceso para su preparacion y composicion farmaceutica que lo contiene. | |
| ES2058945T3 (es) | Materiales dentales. | |
| DE3850044D1 (de) | Azelastin-Embonat, Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen, die als Wirkstoff Azelastin-Embonat enthalten. | |
| NZ234034A (en) | Compositions containing a crownether bound to a polysaccharide | |
| DE3879837D1 (de) | Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen. | |
| ATE49956T1 (de) | N,n-bis-(4fluorophenyl)carbamoylacetohydroxams|ure und diese enthaltende pharmazeutische zusammensetzungen. | |
| TH54857A3 (th) | องค์ประกอบตัวใหม่และการใช้ | |
| MX7484A (es) | Procedimiento para la preparacion de azabiciclo eteres/esteres, producto obtenido y composicion farmaceutica que lo incluye. | |
| ATE32073T1 (de) | Karbonsaeureamidguanidine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen. |